Clinical trial
A Prospective, Multicenter, Post-marketing Phase IV Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma (HCC)
NCT04297254 is registered in ClinicalTrials.gov with Eisai Pharmaceuticals India Pvt. Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multicenter, Post-marketing Phase IV Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma (HCC)
- Lead sponsor
- Eisai Pharmaceuticals India Pvt. Ltd
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- February 4, 2021
- Completion date
- July 31, 2023
- Enrollment
- 50 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.